Format

Send to

Choose Destination
Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02380-17. doi: 10.1128/AAC.02380-17. Print 2018 May.

In Vitro Activity of Lefamulin against Sexually Transmitted Bacterial Pathogens.

Author information

1
Nabriva Therapeutics GmbH, Vienna, Austria susanne.paukner@nabriva.com.
2
Nabriva Therapeutics GmbH, Vienna, Austria.
3
Statens Serum Institut, Microbiology and Infection Control, Copenhagen, Denmark.

Abstract

The pleuromutilin antibiotic lefamulin demonstrated in vitro activity against the most relevant bacterial pathogens causing sexually transmitted infections (STI), including Chlamydia trachomatis (MIC50/90, 0.02/0.04 mg/liter; n = 15), susceptible and multidrug-resistant Mycoplasma genitalium (MIC range, 0.002 to 0.063 mg/liter; n = 6), and susceptible and resistant Neisseria gonorrhoeae (MIC50/90, 0.12/0.5 mg/liter; n = 25). The results suggest that lefamulin could be a promising first-line antibiotic for the treatment of STI, particularly in populations with high rates of resistance to standard-of-care antibiotics.

KEYWORDS:

Chlamydia trachomatis; Mycoplasma genitalium; Neisseria gonorrhoeae; lefamulin; pleuromutilin; sexually transmitted diseases; sexually transmitted infection

PMID:
29530863
PMCID:
PMC5923106
DOI:
10.1128/AAC.02380-17
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center